The company wants to be able to explain or 'contextualize' responders vs non-responders to 2-73. This helps validate efficacy signal (if any). Disease stage, drug plasma levels, S1 type, S1 mRNA levels, and now potentially some of these genes' activations. (This list is in rough order of the MOA stream.)
It could be valuable. Or not. Foremost, we need reliable efficacy signal in large, controlled trials. Watch for trial results.
Market Data 
Markets 
AI
